wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 7. no 4. December 2002  

Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma

National Jewish Medical and Research Center

Reprinted from the Journal of Allergy and Clinical Immunology, 2001; 107: 397-416 with kind permission of Mosby, Inc.

Tłumaczenie: dr med. Barbara Bieńkiewicz

Several classes of medications are available for the treatment of asthma, and often they must be taken concurrently to achieve asthma control. Based on the understanding of asthma as an innammatory disease, the National Heart Lung and Blood Institute guidelines provide a stepwise approach to pharmacologic therapy. Corticosteroid therapy, principally inhaled corticosteroid (ICS) therapy, is considered the most effective anti- innammatory treatment. In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended treatment option. A combination-product inhaler (Advair, Seretide) was developed to treat both the innammatory and bronchoconstric. tive components of asthma by delivering a dose of the ICS, nu- ticasone propionate, and a dose of the long-acting b2-adrenergic (LABA) bronchodilator, salmeterol. The Advair Diskus is available in 3 strengths of nuticasone propionate (100, 250, and 500 µg) and a fixed dose (50 µg) of salmeterol. Combination treat. ment with both ICS and LABA provides greater asthma control than increasing the ICS dose alone, while at the same time reducing the frequency and perhaps the severity of exacerbations. Furthermore, salmeterol added to ICS therapy provides superior asthma control compared with the addition of leukotriene modifiers or theophylline. The superior control is likely a consequence of the complementary actions of the drugs when taken together, including the activation of the glucocorti- coid receptor by salmeterol. By combining anti-infammatory treatment with a long.acting b2-agonist in a single inhaler (1 inhalation twice daily), physicians can provide coverage for both the innammatory and bronchoconstrictive aspects of asthma without introducing any new or unexpected adverse consequences. The most common drug-related adverse events were those known to be attributable to the constituent medications (ICS therapy and/or LABA therapy). Although the benefits of combined ICS plus LABA therapy can be achieved with separate inhalers, the convenience of the combination product may improve patient adherence and may therefore reduce the morbidity of asthma. (J Allergy Clin Immunol 2001; 107: 397-416.)
Alergia Astma Immunologia, 2002; 7(4): 183-203

keywords: astma, Advair (Seretide), salmeterol, propionian flutikazonu, terapia łączona, Seretide, leki przeciwleukotrienowe, zaostrzenie, Serevent, Flovent, asthma, Advair (Seretide), salmeterol, fluticasone propionate, combination therapy, Seretide, leukotriene m

pages: from 183 to 203

estimated time of download (246 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.